Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T12:05:56.081Z.
Calculation as of: 2026-10-06T12:05:56.081Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 3557795f844472894604fcbd35c20595803ff4fe2165ab850e9e673e91650e7f
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$32.31M
Price/FCF Ratio
N/A
TTM Avg
507.99
3Y Avg
507.99
5Y Avg
507.99
Market Cap
$31.36M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BeyondSpring Inc. (BYSI) | $32.32M | N/A | N/A | N/A | N/A |
| EUDA Health Holdings Limited (EUDA)vs › | $32.31M | N/A | 507.99 | 507.99 | 507.99 |
| Baird Medical Investment Holdings Limited (BDMD)vs › | $31.36M | N/A | N/A | N/A | N/A |
| Aligos Therapeutics, Inc. (ALGS)vs › | $33.42M | N/A | N/A | N/A | N/A |
| Grace Therapeutics, Inc. (GRCE)vs › | $33.52M | N/A | N/A | N/A | N/A |
| Context Therapeutics Inc. (CNTX)vs › | $30.92M | N/A | N/A | N/A | N/A |
| CervoMed Inc. (CRVO)vs › | $30.65M | N/A | N/A | N/A | N/A |
| Accuray Incorporated (ARAY)vs › | $35.89M | N/A | 8.65 | 28.12 | 30.77 |
| DocGo Inc. (DCGO)vs › | $36.05M | N/A | 2.50 | 3.99 | 20.14 |
| aTyr Pharma, Inc. (ATYR)vs › | $28.43M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
